Abstract
Malignant gliomas remain incurable with current interventions. Encouraging investigational approaches include the use of genetically modified herpes simplex-1 (HSV-1) viruses as direct cytotoxic agents. Combining attenuated HSV-1 with standard therapy, human U-87 malignant glioma xenografts grown in the hind limb or intracranially in athymic nude mice were exposed to ionizing radiation, inoculated with genetically modified HSV R3616, or received both virus and radiation. The combination of virus with fractionated ionizing radiation suggests a synergistic action and results in reduced tumor volumes and longer survivals when compared with treatment with either modality alone.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Brain Neoplasms / mortality
-
Brain Neoplasms / radiotherapy
-
Brain Neoplasms / therapy*
-
Brain Neoplasms / virology
-
Cancer Vaccines / therapeutic use
-
Cancer Vaccines / virology*
-
Combined Modality Therapy
-
Female
-
Glioma / mortality
-
Glioma / radiotherapy
-
Glioma / therapy*
-
Glioma / virology
-
Herpesvirus 1, Human*
-
Humans
-
Immunohistochemistry
-
Mice
-
Mice, Nude
-
Neoplasm Transplantation
-
Random Allocation
-
Soft Tissue Neoplasms / mortality
-
Soft Tissue Neoplasms / radiotherapy
-
Soft Tissue Neoplasms / therapy
-
Soft Tissue Neoplasms / virology
-
Survival Rate
-
Tumor Cells, Cultured
-
X-Rays